140 related articles for article (PubMed ID: 30549269)
21. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Sita TL; Kouri FM; Hurley LA; Merkel TJ; Chalastanis A; May JL; Ghelfi ST; Cole LE; Cayton TC; Barnaby SN; Sprangers AJ; Savalia N; James CD; Lee A; Mirkin CA; Stegh AH
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4129-4134. PubMed ID: 28373576
[TBL] [Abstract][Full Text] [Related]
22. Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02.
Lohmann B; Le Rhun E; Silginer M; Epskamp M; Weller M
Oncol Lett; 2020 Apr; 19(4):2649-2656. PubMed ID: 32218815
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Huang H; Lin H; Zhang X; Li J
Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
[TBL] [Abstract][Full Text] [Related]
24. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
25. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
26. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
27. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
Juillerat-Jeanneret L; Bernasconi CC; Bricod C; Gros S; Trepey S; Benhattar J; Janzer RC
Cancer Invest; 2008 Jul; 26(6):597-609. PubMed ID: 18584351
[TBL] [Abstract][Full Text] [Related]
29. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.
Pallis M; Abdul-Aziz A; Burrows F; Seedhouse C; Grundy M; Russell N
Br J Haematol; 2012 Oct; 159(2):191-203. PubMed ID: 22934750
[TBL] [Abstract][Full Text] [Related]
30. Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction.
Göder A; Nagel G; Kraus A; Dörsam B; Seiwert N; Kaina B; Fahrer J
Carcinogenesis; 2015 Aug; 36(8):817-31. PubMed ID: 25998848
[TBL] [Abstract][Full Text] [Related]
31. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional control of O
Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
[TBL] [Abstract][Full Text] [Related]
33. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents.
Szeliga M; Zgrzywa A; Obara-Michlewska M; Albrecht J
J Neurochem; 2012 Nov; 123(3):428-36. PubMed ID: 22888977
[TBL] [Abstract][Full Text] [Related]
34. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
35. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
36. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
38. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
39. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
40. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
